English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
“In the past 25 years that I have worked with these critically ill newborns, the only treatment advance for HII has been therapeutic hypothermia—or whole-body cooling—to prevent brain damage,” says Snyder, professor and director of the Center for Stem Cells & Regenerative Medicine at Sanford Burnham Prebys. “When my lab first isolated human neural stem cells in the 1990s, I immediately thought of their potential to help these children.”
Of every 1,000 babies born in the U.S., two to four experience HII. Possible causes range from umbilical cord compression and disrupted maternal blood pressure to early separation of the placenta from the uterus. Standard treatment includes therapeutic hypothermia, breathing assistance and life support. Approximately 10% to 20% of affected infants develop cerebral palsy, epilepsy, an intellectual disability or additional permanent neurological disorders. The subsequent lifelong medical and rehabilitative care is estimated to cost $1 million per child. Indirect costs based on the impact on family dynamics are estimated to be two- to five-fold greater.
“We hope to protect a subset of newborns from developing more serious neurological conditions by focusing on the brain cells that are simply stunned, not destroyed, from the insult—and hence potentially salvageable,” says Snyder. “If we augment the injured area with neural stem cells, we may be able to restore some balance to the injured region. We might be able to rescue some of the nerve cells that are hanging on the precipice between life and death, and perhaps help infants reach their developmental milestones.” Snyder first isolated human neural stem cells in 1998, a landmark discovery for the stem cell field. Over the past two decades, human neural stem cells have been tested extensively for their therapeutic potential. The cells have been studied in animal models of Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal cord injury and childhood neurodegenerative diseases. Related human neural stem cells have been evaluated in clinical trials for adult brain tumors.
“These cells are exceptionally well characterized,” explains Snyder. “We know that they are drawn to injured regions like a magnet, we know they make a cocktail of healing factors and we know they soak up toxins in damaged areas. These characteristics make them very promising therapies, particularly for the developing pediatric brain.” The grant will allow Snyder and his team to conduct animal studies to determine the optimal dose, location and timing to introduce neural stem cells to rescue at-risk brain cells. At the end of the project, which is anticipated to take 2.5 years, Snyder plans to present a pre-IND package to the FDA. He hopes to next launch a Phase 1b/2a clinical trial in newborns with HII to evaluate the neuroprotective effects of human neural stem cells.
“Today, we cross an important threshold,” says Snyder. “We are one step closer to a future where we may be able to protect some newborns from an unanticipated birth injury—and help parents give their children the best possible start in the world.”
###
About Sanford Burnham Prebys Medical Research Institute
Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.
scraped from https://www.newswise.com/articles/4-96-million-cirm-grant-awarded-to-sanford-burnham-prebys-to-help-the-tiniest-patients
